Omada Health announced the introduction of GLP-1 medication prescribing within its digital care platform to support members managing obesity, diabetes, and related metabolic conditions. According to the company, this new capability allows Omada clinicians to evaluate, prescribe, and monitor glucagon-like peptide-1 receptor agonists as part of personalized treatment plans that integrate behavioral coaching, nutrition, and physical activity guidance.
The company said that the service aims to streamline access to evidence-based medication options for eligible members while maintaining continuity of care through its virtual ecosystem. Omada claims that its clinicians will assess clinical appropriateness, oversee ongoing medication management, and provide education to help members use GLP-1 therapies safely and effectively in conjunction with lifestyle interventions.
Omada stated that the rollout responds to a significant increase in member demand for holistic approaches that combine pharmacotherapy with long-term behavior change. The company emphasized that its integrated care model is designed to address both biological and behavioral aspects of metabolic disease, improving engagement and health outcomes while reducing costs for employers and health plans.
According to Omada, the expansion builds on its recent data demonstrating improved outcomes for members who have used its program alongside GLP-1 therapy. The company said that the new prescribing capability will initially be offered to select populations, with plans to expand across its platform in 2026 as part of its broader metabolic health strategy.
